%0 Journal Article
%T Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance
%A Mari Nygˋrd
%A Bo Terning Hansen
%A Joakim Dillner
%A Christian Munk
%A Kristj芍n Oddsson
%A Laufey Tryggvadottir
%A Maria Hortlund
%A Kai-Li Liaw
%A Erik J. Dasbach
%A Susanne Kr邦ger Kjˋr
%J PLOS ONE
%D 2014
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0088323
%X Background Infection with high-risk human papillomavirus (HPV) is causally related to cervical, vulvar and vaginal pre-invasive neoplasias and cancers. Highly effective vaccines against HPV types 16/18 have been available since 2006, and are currently used in many countries in combination with cervical cancer screening to control the burden of cervical cancer. We estimated the overall and age-specific incidence rate (IR) of cervical, vulvar and vaginal cancer and pre-invasive neoplasia in Denmark, Iceland, Norway and Sweden in 2004每2006, prior to the availability of HPV vaccines, in order to establish a baseline for surveillance. We also estimated the population attributable fraction to determine roughly the expected effect of HPV16/18 vaccination on the incidence of these diseases. Methods Information on incident cervical, vulvar and vaginal cancers and high-grade pre-invasive neoplasias was obtained from high-quality national population-based registries. A literature review was conducted to define the fraction of these lesions attributable to HPV16/18, i.e., those that could be prevented by HPV vaccination. Results Among the four countries, the age-standardised IR/105 of cervical, vaginal and vulvar cancer ranged from 8.4每13.8, 1.3每3.1 and 0.2每0.6, respectively. The risk for cervical cancer was highest in women aged 30每39, while vulvar and vaginal cancers were most common in women aged 70+. Age-standardised IR/105 of cervical, vulvar and vaginal pre-invasive neoplasia ranged between 138.8ˋ183.2, 2.5ˋ8.8 and 0.5ˋ1.3, respectively. Women aged 20ˋ29 had the highest risk for cervical pre-invasive neoplasia, while vulvar and vaginal pre-invasive neoplasia peaked in women aged 40ˋ49 and 60ˋ69, respectively. Over 50% of the observed 47,820 incident invasive and pre-invasive cancer cases in 2004ˋ2006 can be attributed to HPV16/18. Conclusion In the four countries, vaccination against HPV 16/18 could prevent approximately 8500 cases of gynecological cancer and pre-cancer annually. Population-based cancer and vaccination registries are essential to assess the predicted public health effects of HPV vaccination.
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0088323